Results for tag: "Plant Based Vaccines"

Within the broader vaccines market, plant-based vaccines represent a nascent and innovative segment that utilizes plants as bioreactors to produce vaccine antigens. Plant-based vaccine production employs molecular farming techniques, wherein genetic modifications enable plants to express protein antigens that, once purified, can be used as vaccines. This platform offers potential advantages over traditional vaccine production methods in terms of scalability, safety, and cost-effectiveness, as it reduces reliance on animal or cell culture systems, and can be adapted swiftly to produce vaccines for emerging pathogens. The plant-based vaccine market is driven by the need for more efficient and rapid production methodologies that can address a variety of disease targets. Investment in research and development in this area is driven by a combination of academic institutions, public health organizations, and private sector interests looking to harness the speed and versatility that plant-based systems offer. Notable companies engaged in the development and commercialization of plant-based vaccines include Medicago, which utilizes a relative of the tobacco plant to produce vaccine candidates; iBio, which leverages its FastPharming System to quickly develop proteins for vaccines; and Kentucky BioProcessing, which focuses on using tobacco plants in producing recombinant proteins for vaccines. These companies, among others, are at the forefront of translating the promise of plant-based vaccine technology into practical health solutions. Show Less Read more